Pharmerging

REPORT HIGHLIGHTS

Global Pharmerging Market to Reach US$3.8 Trillion by 2032

The global market for Pharmerging estimated at US$2.1 Trillion in the year 2025, is expected to reach US$3.8 Trillion by 2032, growing at a CAGR of 8.7% over the analysis period 2025-2032. Branded Generics Type, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.1 Trillion by the end of the analysis period. Growth in the Patented Drugs Type segment is estimated at 11.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$620.4 Billion While China is Forecast to Grow at 8.5% CAGR

The Pharmerging market in the U.S. is estimated at US$620.4 Billion in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$669.7 Billion by the year 2032 trailing a CAGR of 8.5% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global Pharmerging Market - Key Trends & Drivers Summarized

Why Is the Pharmerging Market Gaining Prominence as a Key Driver of Growth in the Global Pharmaceutical Industry?

The pharmerging market is gaining prominence as a key driver of growth in the global pharmaceutical industry due to the rapid expansion of healthcare infrastructure, increasing prevalence of chronic diseases, and rising affordability of medicines in emerging economies. The term "pharmerging" refers to pharmaceutical markets in emerging countries that are experiencing rapid growth in pharmaceutical consumption and sales. These countries, which include regions such as China, India, Brazil, Russia, and Southeast Asia, are characterized by expanding middle-class populations, improving healthcare access, and growing investment in healthcare infrastructure. As a result, the demand for pharmaceuticals, including generic drugs, over-the-counter (OTC) medications, and innovative therapies, is increasing significantly in these markets.

Pharmerging markets are playing a critical role in driving the global pharmaceutical industry’s growth as they offer substantial opportunities for pharmaceutical companies to expand their presence and tap into new revenue streams. The increasing adoption of Western-style healthcare practices, coupled with government initiatives to improve healthcare coverage and affordability, is boosting the demand for medicines in these regions. Moreover, the rising incidence of chronic diseases such as diabetes, cardiovascular disorders, and cancer—driven by changing lifestyles, urbanization, and aging populations—is creating a strong demand for both chronic and specialty medications. The pharmerging markets’ growing share of global pharmaceutical sales is making them a strategic focus for multinational pharmaceutical companies seeking to offset slowing growth in mature markets such as North America and Europe.

How Are Technological Advancements and Healthcare Reforms Transforming the Pharmerging Market?

Technological advancements and healthcare reforms are transforming the pharmerging market by improving healthcare delivery, enhancing drug accessibility, and facilitating the adoption of innovative therapies. One of the most significant advancements in this space is the increased use of digital health technologies, such as telemedicine, mobile health applications, and electronic health records (EHRs), which are improving healthcare access and patient outcomes in remote and underserved areas. Telemedicine, in particular, has gained traction in pharmerging markets as it enables healthcare providers to offer consultations, diagnostics, and treatment recommendations to patients without the need for physical visits. The use of mobile health applications for chronic disease management, medication adherence, and health education is supporting patient engagement and encouraging the adoption of preventive healthcare practices.

The integration of digital technologies in healthcare is also enabling the collection and analysis of health data, supporting better disease management and healthcare planning. EHRs and health information systems are being used to streamline patient data management, improve treatment outcomes, and reduce medical errors. These technologies are helping pharmerging markets overcome challenges related to healthcare accessibility, resource constraints, and healthcare quality, supporting the overall growth of the pharmaceutical sector. Furthermore, the implementation of health technology assessment (HTA) frameworks and pharmacoeconomic evaluations is enabling governments and healthcare payers in pharmerging markets to make informed decisions regarding the adoption of new therapies and healthcare interventions, ensuring that healthcare resources are used efficiently.

Healthcare reforms aimed at expanding healthcare access and affordability are also playing a pivotal role in transforming the pharmerging market. Many pharmerging countries are implementing universal health coverage (UHC) schemes, national health insurance programs, and price control measures to ensure that essential medicines and healthcare services are accessible to a larger segment of the population. For example, the Indian government’s “Ayushman Bharat” health insurance scheme and China’s National Reimbursement Drug List (NRDL) reforms are increasing the availability and affordability of medications for millions of citizens. These reforms are driving demand for both branded and generic drugs, creating new opportunities for pharmaceutical companies to reach underserved populations.

Additionally, the adoption of biosimilars and generic drugs is gaining momentum in pharmerging markets as governments promote the use of cost-effective therapies to reduce healthcare expenditures. Biosimilars, which are lower-cost versions of biologic drugs, are being increasingly accepted as alternatives to expensive biologic therapies in treating conditions such as cancer, rheumatoid arthritis, and diabetes. The use of generics is also being encouraged through policies that support local manufacturing and faster regulatory approvals. These measures are helping to lower drug prices and increase the availability of affordable treatments, supporting the growth of the pharmaceutical market in these regions. As technological advancements and healthcare reforms continue to reshape the pharmerging market, they are making it more accessible, efficient, and attractive for pharmaceutical companies looking to expand their global footprint.

What Role Do Government Initiatives and Local Manufacturing Play in Driving the Growth of the Pharmerging Market?

Government initiatives and local manufacturing are playing a pivotal role in driving the growth of the pharmerging market by fostering an environment that supports pharmaceutical production, reduces dependency on imports, and enhances healthcare affordability. Many pharmerging countries are implementing policies and programs aimed at boosting domestic pharmaceutical production, encouraging foreign direct investment (FDI), and creating favorable business conditions for both local and multinational pharmaceutical companies. These initiatives are designed to develop self-sufficiency in drug production, ensure a stable supply of essential medicines, and promote the use of locally produced generics and biosimilars.

Local manufacturing is particularly significant in pharmerging markets as it helps reduce production costs, lower drug prices, and improve access to affordable medications. Countries such as India and China have established themselves as leading global hubs for pharmaceutical manufacturing, supplying a large portion of the world’s generic drugs and active pharmaceutical ingredients (APIs). The presence of a strong local manufacturing base enables these countries to produce high-quality pharmaceuticals at competitive prices, making essential medicines more accessible to domestic and international markets. Government support in the form of tax incentives, subsidies, and infrastructure development is further strengthening the pharmaceutical manufacturing sector in these regions, driving market growth.

Government initiatives aimed at promoting local pharmaceutical innovation and R&D are also influencing the growth of the pharmerging market. Programs that support the development of new drug formulations, novel drug delivery systems, and biosimilars are helping local pharmaceutical companies enhance their product portfolios and compete in the global market. For instance, China’s “Made in China 2025” initiative and India’s “Pharma Vision 2020” are focused on boosting the domestic pharmaceutical industry’s capacity for innovation and increasing its contribution to the global pharmaceutical value chain. The establishment of pharmaceutical research parks, incubation centers, and public-private partnerships is facilitating collaboration between academia, industry, and government, supporting the development of innovative drug products that address the specific healthcare needs of pharmerging markets.

Moreover, the implementation of regulatory reforms aimed at streamlining the drug approval process and ensuring compliance with international quality standards is creating a more conducive environment for pharmaceutical market growth. Regulatory bodies in pharmerging markets are adopting international guidelines such as Good Manufacturing Practices (GMP) and harmonizing their regulatory frameworks with global standards to facilitate faster market entry and increase the competitiveness of locally produced drugs. These reforms are encouraging multinational pharmaceutical companies to establish local manufacturing facilities and collaborate with local partners, further boosting the growth of the pharmerging market.

The emphasis on improving healthcare affordability and accessibility through government policies is also driving demand for pharmaceutical products in pharmerging markets. Governments are implementing pricing controls, bulk procurement programs, and reimbursement policies to ensure that essential medicines are available at affordable prices. These measures are supporting the adoption of cost-effective therapies such as generics and biosimilars, driving the growth of the pharmaceutical market. As government initiatives and local manufacturing capabilities continue to evolve, they are playing a crucial role in shaping the future of the pharmerging market and creating new growth opportunities for the pharmaceutical industry.

What Factors Are Driving the Growth of the Global Pharmerging Market?

The growth in the global pharmerging market is driven by several factors, including the expanding middle-class population, increasing healthcare expenditures, rising prevalence of chronic diseases, and the growing focus on healthcare infrastructure development in emerging economies. One of the primary growth drivers is the rapid economic development and rise in disposable incomes in pharmerging countries. As the middle-class population expands, more individuals can afford to spend on healthcare services and pharmaceutical products, leading to increased demand for both prescription and over-the-counter medications. The growing purchasing power of consumers in countries such as China, India, Brazil, and Russia is contributing to the expansion of the pharmaceutical market, making these regions attractive for pharmaceutical companies looking to diversify their revenue streams.

The increasing healthcare expenditures in pharmerging markets are another key factor contributing to market growth. Governments and private sectors in these regions are investing heavily in healthcare infrastructure, expanding healthcare coverage, and implementing policies to improve the availability and affordability of medical services. These investments are enhancing the quality of healthcare delivery and increasing the utilization of pharmaceutical products. The establishment of new hospitals, clinics, and healthcare facilities is creating demand for a wide range of medications, from acute care drugs to specialty therapies, supporting the growth of the pharmaceutical market in these regions.

The rising prevalence of chronic diseases such as diabetes, hypertension, cardiovascular disorders, and cancer is further driving the growth of the pharmerging market. The increasing incidence of chronic conditions, driven by factors such as urbanization, aging populations, and changes in lifestyle, is creating a strong demand for long-term medications and specialty therapies. The growing burden of chronic diseases is prompting governments and healthcare providers to prioritize disease prevention, early diagnosis, and effective management, leading to increased consumption of pharmaceuticals. The availability of innovative therapies, such as biologics and biosimilars, is supporting the treatment of chronic and complex diseases, further boosting market growth.

Moreover, the expanding pharmaceutical manufacturing capabilities in pharmerging markets are contributing to the growth of the global pharmaceutical supply chain. Countries such as India and China have established themselves as leading suppliers of APIs and generic drugs, providing cost-effective pharmaceutical products to both domestic and international markets. The presence of a strong manufacturing base is enabling pharmerging countries to meet the growing demand for pharmaceuticals, reduce dependency on imports, and increase their share of global pharmaceutical exports. The development of pharmaceutical manufacturing clusters, free trade zones, and export promotion programs is further enhancing the competitiveness of pharmerging markets in the global pharmaceutical industry.

Additionally, the increasing focus on public health and the implementation of universal health coverage schemes in pharmerging markets are creating new opportunities for pharmaceutical market expansion. Governments are implementing policies to improve healthcare access and coverage, particularly for low-income populations and rural communities. The expansion of health insurance schemes, the inclusion of more drugs in reimbursement lists, and the establishment of primary healthcare networks are driving demand for a wide range of pharmaceutical products. The focus on expanding access to essential medicines and healthcare services is supporting the growth of the pharmaceutical market in pharmerging regions.

Furthermore, the impact of the COVID-19 pandemic has accelerated investments in healthcare infrastructure and pharmaceutical production in pharmerging markets. The pandemic highlighted the need for robust healthcare systems and self-sufficiency in pharmaceutical production. Governments in pharmerging markets are increasing investments in healthcare infrastructure, public health initiatives, and pharmaceutical manufacturing capacity to strengthen their healthcare systems and ensure the availability of essential medicines. These investments are expected to drive long-term growth in the pharmerging market, as countries seek to enhance their healthcare resilience and improve health outcomes for their populations. As these factors converge, the global pharmerging market is poised for robust growth, supported by expanding healthcare access, rising demand for innovative therapies, and the increasing emphasis on developing local pharmaceutical manufacturing capabilities across various emerging economies.

SCOPE OF STUDY:

The report analyzes the Pharmerging market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Branded Generics Type, Patented Drugs Type, OTC Pharmaceuticals Type, Biosimilars Type, Vaccines Type); Therapeutic Area (Oncology Therapeutic Area, Cardiovascular Therapeutic Area, Anti-Infectives Therapeutic Area, Diabetes Therapeutic Area, Respiratory Therapeutic Area, Other Therapeutic Areas); Distribution Channel (Retail Pharmacies Distribution Channel, Hospital Pharmacies Distribution Channel, Online Distribution Channel, Other Distribution Channels); Formulation (Solid Oral Formulation, Liquid Oral Formulation, Other Formulations)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• Abbott Laboratories
• AbbVie, Inc.
• Alexion Pharmaceuticals, Inc.
• Allergan PLC
• Amgen, Inc.
• Aspen Pharmacare Holdings Ltd.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Baxter International, Inc.
• Bayer AG
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• CSL Behring
• Daiichi Sankyo Co., Ltd.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Endo International PLC
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Grifols SA
• H. Lundbeck A/S
• Hospira, Inc.
• Johnson & Johnson
• Kyowa Hakko Kirin Co., Ltd.
• Mallinckrodt Pharmaceuticals
• Mitsubishi Tanabe Pharma Corporation
• Mylan Pharmaceutical Pvt. Ltd.
• Novartis AG
• Novo Nordisk A/S
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi SA
• Shire PLC
• Stada Arzneimittel AG
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB SA

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more